


Unlocking the Secrets of Enhancer Biology with GWAS

Dennis J. Hazelett, Cedars-Sinai, LA

1. Best SNPs
2. Best Enhancers



“Houston we have a Problem”: (Tom Hanks)

FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs


Simon G. Coetzee^{1,2}, Suhn K. Rhie^{1,2}, Benjamin P. Berman^{1,2,3}, Gerhard A. Coetzee^{1,2,4,*} and Houtan Noushmehr^{1,2,3,*}

¹Norris Cancer Center, ²Department of Preventive Medicine, ³Epigenome Center and ⁴Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Received March 20, 2012; Revised April 26, 2012; Accepted May 13, 2012

This results in a significant reduction in candidate functional SNPs to be tested.
(From 10's of thousands to <1000)

Too many candidates!



Genome-wide two important Questions

Show me the best risk SNPs/enhancers

And

Show me the Genes
(Cuba Gooding)




1. Best risk SNPs

Prostate Cancer fine-mapping of multi-ethnic cohorts overlaid FunciSNP

- Ying Han (Haiman)
- Dennis Hazelett (Coetzee)


Rationale

- Better coverage of genetic variation: imputed to 1000 Genomes
- Empowered by the large sample size
- Multiethnic populations help reduce the set of candidate SNPs



- Comprehensive functional annotation of all candidate SNPs

The most associated SNPs at 57 loci




Compared to the index SNP

- > 1 order of magnitude change in the p-value } Better marker identified for 32 index SNPs
- < 1 order of magnitude change in the p-value }
- Index variant remains the most significant } 25 index SNPs or their proxies remain the most associated SNPs

12q13.13

Plotted SNPs



SNPs per region


| Selection Criteria | SNPs/region |
|--|--|
| All SNPs (1K) at 1MB/region | ~3,000 (MAF \geq 1%) |
| SNPs $r^2 \geq 0.1$ with index SNP | ~40 |
| SNPs $r^2 \geq 0.5$ in biofeatures | 9.8 |
| SNPs significantly fine mapped | 12 - 22 |
| SNPs significantly fine mapped AND in biofeatures | 3.5 - 5.4 (2.4 common in two independent studies) |

Summary

Among 69 known prostate cancer risk loci

- 57 loci were statistically significant in our study
- We identified better markers at 32 loci
- 3-5 putatively functional, finemapped SNPs for followup studies

2. Best Enhancers



How we chose to define and classify putative regulatory sites in LNCaP


- DNasel hypersensitivity sites within H3K27Ac regions (Duke set)
- response elements for all motifs in Factorbook and HOCOMOCO, plus a few from Homer
- throw out bottom 5% of response elements
- make a big data grid; rows of DHS sites, columns of response element counts. Pearson correlation of REs, followed by unsupervised clustering (avg link)
- regulatory sites = includes “Enhancer” >1kb distance from TSS, “Promoter” <1 kb TSS

clustering of TF motifs by correlation reveals potentially functional subcategories of regulatory sites


0

clustered by average distance


-1




Create classification scheme based on TF motif clustering




Number of DNasel HS sites by class in LNCaP




Class I – Class V regulatory regions are spatially differentiated relative to transcription start sites



Prostate Cancer risk SNPs are enriched for Group II enhancers





Summary

- LNCaP enhancers can be classified according to TF binding motifs
- Risk SNPs are highly enriched in a specific class of enhancers
- A short-list of best risk enhancers/ SNPs was compiled

So, back to two important questions

1. Show me the best risk SNPs/enhancers ✓

But what remains:


2. Show me the Genes as
Cuba Gooding would ask

- eQTL
- 4C
- CRISPR/Cas9




Target Gene Identification

3C, 4C, 5C and Hi-C



Transgenic Mouse Models




CRISPRs
Delete enhancers


RNA




eQTL




CRISPR/Cas9



Integration




Venn diagram of idealized target genes identified using our 3 independent approaches, resulting in common genes most likely to functionally be involved in PCa risk at each enhancer.



CRISPR Experimental Pipeline

Esther Tak



Acknowledgements and Thanks

- Dennis Hazelett (Coetzee lab)
- Ying Han (Haiman group)
- Gerry Coetzee
 - Chunli Yan
 - Yu Guo (Phoebe)
 - Hang Yang
 - Sonya Liu
- Dennis Hazelett
 - Simon Coetzee
- Peggy Farnham
 - Malaina Gaddis
 - Esther Tak
 - Zhifei Luo
- Charlie Nicolet & NGS
- Chris Haiman
- Wange Lu
- Josh Millstein

Funding: R01CA136924, R01CA190182